SE441977B - Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen - Google Patents

Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen

Info

Publication number
SE441977B
SE441977B SE7903240A SE7903240A SE441977B SE 441977 B SE441977 B SE 441977B SE 7903240 A SE7903240 A SE 7903240A SE 7903240 A SE7903240 A SE 7903240A SE 441977 B SE441977 B SE 441977B
Authority
SE
Sweden
Prior art keywords
certain
antiandrogen
prostate
acetate
estrogen
Prior art date
Application number
SE7903240A
Other languages
English (en)
Swedish (sv)
Other versions
SE7903240L (sv
Inventor
F Neumann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SE7903240L publication Critical patent/SE7903240L/
Publication of SE441977B publication Critical patent/SE441977B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE7903240A 1978-04-17 1979-04-11 Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen SE441977B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782817157 DE2817157A1 (de) 1978-04-17 1978-04-17 Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie

Publications (2)

Publication Number Publication Date
SE7903240L SE7903240L (sv) 1979-10-18
SE441977B true SE441977B (sv) 1985-11-25

Family

ID=6037493

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7903240A SE441977B (sv) 1978-04-17 1979-04-11 Medel for profylaktisk och terapeutisk behandling av prostatahyperplasi pa basis av en blandning av viss antiostrogen och viss antigonadotropt verkande antiandrogen

Country Status (13)

Country Link
US (1) US4310523A (de)
JP (1) JPS5513261A (de)
AU (1) AU528179B2 (de)
BE (1) BE875634A (de)
CA (1) CA1134271A (de)
CH (1) CH641679A5 (de)
DE (1) DE2817157A1 (de)
GB (1) GB2018591B (de)
IT (1) IT1119733B (de)
LU (1) LU81153A1 (de)
NL (1) NL7901961A (de)
SE (1) SE441977B (de)
ZA (1) ZA791797B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
DE3486090T2 (de) * 1983-12-12 1993-08-05 Kaszynski Edwin G Haarwuchsmodifikation.
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
ES2072424T3 (es) 1989-01-27 1995-07-16 Immunolytics Inc Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
CA2062973C (en) * 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE232743T1 (de) * 1994-06-27 2003-03-15 Neutron Therapies Inc Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU5984196A (en) * 1995-06-07 1996-12-30 Merck & Co., Inc. Treatment and prevention of prostatic disease
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1321146A3 (de) * 1998-03-11 2004-06-02 Endorecherche Inc. Typ 5 und Typ 3 17 Beta-Hydroxisteroid-Dehydrogenasehemmer und Verfahren zu ihrer Anwendung
MXPA00008868A (es) * 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US8288342B2 (en) * 2008-10-10 2012-10-16 Teva Women's Health, Inc. Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076823A (en) * 1961-07-03 1963-02-05 Syntex Corp Process for the production of 6-chloro-3-keto-deta steroid compounds
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
DE2817157A1 (de) 1979-10-25
IT1119733B (it) 1986-03-10
GB2018591B (en) 1982-09-08
JPS645007B2 (de) 1989-01-27
GB2018591A (en) 1979-10-24
SE7903240L (sv) 1979-10-18
CH641679A5 (de) 1984-03-15
US4310523A (en) 1982-01-12
ZA791797B (en) 1980-11-26
BE875634A (fr) 1979-10-17
CA1134271A (en) 1982-10-26
JPS5513261A (en) 1980-01-30
IT7921854A0 (it) 1979-04-13
AU4560479A (en) 1979-10-25
AU528179B2 (en) 1983-04-21
LU81153A1 (de) 1979-06-19
NL7901961A (nl) 1979-10-19

Similar Documents

Publication Publication Date Title
EP1602370B1 (de) Synergistische Kombinationen enthaltend einen Renininhibitor für Kardiovaskulären Erkrankungen
RU2113849C1 (ru) Комбинированный препарат для контрацепции на базе природных эстрогенов
US4310523A (en) Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
DE60124600T2 (de) Zusammensetzungen und Verfahren zur Behandlung von Zuständen, die auf Östrogen ansprechen
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
US20220378813A1 (en) Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
DE69022722T2 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US6139873A (en) Combined pharmaceutical estrogen-androgen-progestin
KR100370908B1 (ko) 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제
CN1042296C (zh) 避孕用途的药物制剂的制备方法
US4775661A (en) Combination therapy for treatment of female breast cancer
CN1135176A (zh) 用于绝经前后妇女激素代替疗法中的孕甾醇拮抗剂与具有部分紧张作用的抗雌激素的结合体
DE69117902T2 (de) Progestogen als einziges Kontrazeptivum
ES2261523T3 (es) Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
JPH08510993A (ja) ホルモン補充方法
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CN1171051A (zh) 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物
DE60115274T2 (de) Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
HU215959B (hu) Eljárás 5-metil-izoxazol-4-karbonsav-anilideket vagy 2-hidroxi-etilidén ciano-ecetsav-anilideket tartalmazó, szembetegségek kezelésére helyileg alkalmazható gyógyszerkészítmények előállítására
JPH1129482A (ja) 医薬組成物
JP2003048836A (ja) 効能を保持し無月経を引き起こす超低用量の経口避妊薬
KR20050098296A (ko) 아로마타제 억제제, 프로게스틴 및 에스트로겐의 조합물을포함하는 조성물 및 자궁내막증의 치료를 위한 이의 용도
IE46481B1 (en) Improvements in or relating to broparestrol based therapeutic compositions
DE19849737A1 (de) Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
JPS6067425A (ja) 制癌剤

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7903240-5

Effective date: 19921108

Format of ref document f/p: F